Replimune Group, Inc. (REPL)
15.30
-0.20
(-1.29%)
USD |
NASDAQ |
Aug 31, 16:00
15.29
-0.01
(-0.07%)
After-Hours: 20:00
Replimune Group Cash from Investing (Quarterly) : 49.99M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 49.99M |
| March 31, 2026 | 86.51M |
| December 31, 2025 | 75.12M |
| September 30, 2025 | 84.17M |
| June 30, 2025 | 65.05M |
| March 31, 2025 | -7.70M |
| December 31, 2024 | -46.32M |
| September 30, 2024 | 0.458M |
| June 30, 2024 | 29.77M |
| March 31, 2024 | 23.20M |
| December 31, 2023 | 53.96M |
| September 30, 2023 | 12.68M |
| June 30, 2023 | 7.361M |
| March 31, 2023 | -22.75M |
| December 31, 2022 | -125.10M |
| September 30, 2022 | 0.036M |
| June 30, 2022 | 5.315M |
| Date | Value |
|---|---|
| March 31, 2022 | -4.326M |
| December 31, 2021 | -13.42M |
| September 30, 2021 | -11.05M |
| June 30, 2021 | 26.99M |
| March 31, 2021 | -126.27M |
| December 31, 2020 | 31.42M |
| September 30, 2020 | -44.80M |
| June 30, 2020 | -49.13M |
| March 31, 2020 | 7.841M |
| December 31, 2019 | -65.21M |
| September 30, 2019 | 25.32M |
| June 30, 2019 | 26.81M |
| March 31, 2019 | 10.47M |
| December 31, 2018 | 3.801M |
| September 30, 2018 | -85.11M |
| June 30, 2018 | 4.89M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Moderna, Inc. | 329.00M |
| Kalaris Therapeutics, Inc. | 20.17M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -75.73M |
| Cash from Financing (Quarterly) | 0.80M |
| Free Cash Flow | -280.54M |
| Free Cash Flow Per Share (Quarterly) | -0.7819 |
| Free Cash Flow to Equity (Quarterly) | -76.12M |
| Free Cash Flow to Firm (Quarterly) | -72.66M |
| Free Cash Flow Yield | -20.17% |